Related Experiment Video
Updated: Sep 14, 2025
Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics
Published on: March 15, 2024
Identification of FADS2 as a Contributor of Ferroptosis Escape in Bladder Cancer
Peixin Li1, Shengwen Yao1, Wenqiang Qi1
1Department of Urology, Qilu Hospital of Shandong University, Jinan, Shandong, China.
Abstract:
Ferroptosis is an iron-dependent form of regulated cell death. Previous research indicates that inducing ferroptosis holds significant promise in cancer therapy, particularly for patients who have failed traditional treatments. However, the presence of a ferroptosis escape mechanism in bladder cancer remains unclear, and the therapeutic potential of ferroptosis induction in this context requires further exploration. In this study, bioinformatics analyses and immunohistochemical staining revealed that FADS2 is aberrantly overexpressed in bladder cancer, with its high expression correlating with poor prognosis. Both in vivo and in vitro experiments, including CCK-8 assays, lipid peroxidation assays, iron measurements and ferroptosis-related gene analyses, demonstrated that silencing FADS2 can trigger ferroptosis in bladder cancer cells. Mechanistically, inhibition of the mTOR pathway and SREBP activity was found to reduce FADS2 expression and promote ferroptosis in bladder cancer. In conclusion, this study identifies a critical gene involved in ferroptosis escape in bladder cancer and suggests that FADS2 could serve as a novel prognostic marker and therapeutic target.
Insights
This study reveals that high FADS2 expression promotes bladder cancer survival by inhibiting ferroptosis. Silencing FADS2 triggers cancer cell death, identifying FADS2 as a potential therapeutic target for bladder cancer treatment.
Area of Science:
- Oncology
- Cell Death Research
- Biochemistry
Background:
- Ferroptosis, an iron-dependent cell death, shows promise in cancer therapy, especially for treatment-resistant cancers.
- The mechanisms of ferroptosis evasion in bladder cancer are not well understood, limiting therapeutic strategies.
- Investigating novel pathways for bladder cancer treatment is crucial.
Purpose of the Study:
- To investigate the role of FADS2 in ferroptosis regulation within bladder cancer.
- To explore the potential of targeting FADS2 for bladder cancer therapy.
- To identify FADS2 as a prognostic biomarker for bladder cancer.
Main Methods:
- Bioinformatics analysis and immunohistochemical staining to assess FADS2 expression in bladder cancer.
- In vivo and in vitro experiments (CCK-8, lipid peroxidation, iron assays, gene analysis) to evaluate the effect of FADS2 silencing on ferroptosis.
- Investigation of the mechanistic link between FADS2, mTOR, and SREBP pathways.
Main Results:
- FADS2 is significantly overexpressed in bladder cancer, correlating with poor patient prognosis.
- Silencing FADS2 effectively induces ferroptosis in bladder cancer cells.
- Inhibition of mTOR and SREBP pathways reduces FADS2 expression and enhances ferroptosis.
Conclusions:
- FADS2 plays a critical role in bladder cancer's resistance to ferroptosis.
- Targeting FADS2 presents a promising therapeutic strategy for bladder cancer.
- FADS2 serves as a potential prognostic marker for bladder cancer.
